Literature DB >> 26797658

Open trial of exposure therapy for PTSD among patients with severe and persistent mental illness.

Anouk L Grubaugh1, Joshua D Clapp2, B Christopher Frueh3, Peter W Tuerk4, Rebecca G Knapp5, Leonard E Egede6.   

Abstract

OBJECTIVE: There are few empirical data regarding effective treatment of trauma-related symptoms among individuals with severe mental illness (SMI; e.g., bipolar disorder, schizophrenia). This under-examined clinical issue is significant because rates of trauma and PTSD are higher among individuals with SMI relative to the general population, and there are sufficient data to suggest that PTSD symptoms exacerbate the overall course and prognosis of SMI.
METHOD: 34 veterans with SMI received prolonged exposure (PE) for PTSD using an open trial study design.
RESULTS: Data suggest that PE is feasible to implement, well-tolerated, and results in clinically significant decreases in PTSD severity in patients with SMI. Mean CAPS scores improved 27.2 points from baseline to immediate post [95% CI for mean change: -44.3, - 10.1; p = 0.002, paired t-test, and treatment gains were maintained at 6 months [mean change from baseline to 6-months, -16.1; 95% CI: -31.0, -1.2; p = 0.034, paired t-test].
CONCLUSIONS: The current data support the use of exposure-based interventions for PTSD among individuals with SMI and highlight the need for rigorous randomized efficacy trials investigating frontline PTSD interventions in this patient population.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Exposure therapy; Posttraumatic stress disorder (PTSD); Prolonged exposure; Severe mental illness (SMI); Trauma

Mesh:

Year:  2015        PMID: 26797658     DOI: 10.1016/j.brat.2015.12.006

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  1 in total

1.  Feasibility and Efficacy of Prolonged Exposure for PTSD among Individuals with a Psychotic Spectrum Disorder.

Authors:  Anouk L Grubaugh; Kimberly Veronee; Charles Ellis; Wilson Brown; Rebecca G Knapp
Journal:  Front Psychol       Date:  2017-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.